LEVERAGING AI PLATFORMS TO ANTICIPATE EU JCA DOSSIER RISKS: INSIGHTS FROM EARLY TERMINATIONS
Author(s)
Turgay Ayer, PhD1, Sumeyye Samur, PhD1, Jag Chhatwal, PhD2.
1Value Analytics Labs, Boston, MA, USA, 2Associate Professor and Director of the Institute for Technology Assessment, Harvard Medical School / Massachusetts General Hospital, Boston, MA, USA.
1Value Analytics Labs, Boston, MA, USA, 2Associate Professor and Director of the Institute for Technology Assessment, Harvard Medical School / Massachusetts General Hospital, Boston, MA, USA.
OBJECTIVES: The EU Health Technology Assessment Regulation (EU 2021/2282) introduced Joint Clinical Assessments (JCAs) as the framework for evaluating the relative clinical effectiveness of new medicines. In 2025-2026, the European Commission discontinued JCAs for catequentinib and Tacquell under Article 9(2)-(4). This analysis examined the disclosed reasons to identify actionable insights for health technology developers (HTDs) preparing future JCA value dossiers.
METHODS: A targeted policy analysis was conducted using ValueGen.AI, an AI‑assisted platform for structured evidence and policy synthesis, to integrate publicly available Commission discontinuation notices, the JCA dossier template guidance, the outcomes guidance for JCAs, Implementing Regulation (EU) 2024/1381, and relevant peer-reviewed literature on JCA methodology, PICO scoping, and indirect treatment comparisons (ITCs). Deficiency themes were mapped against the Article 9 obligations framework to identify systematic patterns.
RESULTS: Catequentinib’s JCA was terminated for dossier deficiencies under Article 9(2), including incomplete evidence identification and synthesis, non-compliance with the PICO framework, inadequate literature searches, missing justification for study selection, and absent ITCs. Tacquell’s JCA was discontinued under Article 9(3) following failure to address a second information request from assessors. Cross-case analysis revealed five recurring themes: (1) insufficient justification for how scoped PICOs were addressed; (2) incomplete systematic evidence identification; (3) limited feasibility assessment for ITCs; (4) inadequate methodological transparency for evidence synthesis; and (5) insufficient documentation to allow independent verification of results. These deficiencies primarily concerned the evidence strategy and methodological reproducibility rather than clinical outcomes per se.
CONCLUSIONS: The first JCA discontinuations highlight that methodological transparency, reproducibility, and PICO adherence are essential for assessment completion. HTDs should integrate JCA-specific evidence planning—including ITC feasibility, comprehensive literature searches, and fully documented analytic decisions—early in clinical development. These early enforcement actions and AI‑derived insights together establish important precedents for the evidentiary and documentation standards that future manufacturers should meet to secure successful EU JCAs.
METHODS: A targeted policy analysis was conducted using ValueGen.AI, an AI‑assisted platform for structured evidence and policy synthesis, to integrate publicly available Commission discontinuation notices, the JCA dossier template guidance, the outcomes guidance for JCAs, Implementing Regulation (EU) 2024/1381, and relevant peer-reviewed literature on JCA methodology, PICO scoping, and indirect treatment comparisons (ITCs). Deficiency themes were mapped against the Article 9 obligations framework to identify systematic patterns.
RESULTS: Catequentinib’s JCA was terminated for dossier deficiencies under Article 9(2), including incomplete evidence identification and synthesis, non-compliance with the PICO framework, inadequate literature searches, missing justification for study selection, and absent ITCs. Tacquell’s JCA was discontinued under Article 9(3) following failure to address a second information request from assessors. Cross-case analysis revealed five recurring themes: (1) insufficient justification for how scoped PICOs were addressed; (2) incomplete systematic evidence identification; (3) limited feasibility assessment for ITCs; (4) inadequate methodological transparency for evidence synthesis; and (5) insufficient documentation to allow independent verification of results. These deficiencies primarily concerned the evidence strategy and methodological reproducibility rather than clinical outcomes per se.
CONCLUSIONS: The first JCA discontinuations highlight that methodological transparency, reproducibility, and PICO adherence are essential for assessment completion. HTDs should integrate JCA-specific evidence planning—including ITC feasibility, comprehensive literature searches, and fully documented analytic decisions—early in clinical development. These early enforcement actions and AI‑derived insights together establish important precedents for the evidentiary and documentation standards that future manufacturers should meet to secure successful EU JCAs.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
MSR93
Topic
Methodological & Statistical Research
Topic Subcategory
Artificial Intelligence, Machine Learning, Predictive Analytics
Disease
Oncology